EntryPoint Capital’s Ironwood Pharmaceuticals IRWD Stock Holding History

EntryPoint Capital’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$305K	Buy	86,874 +20,249	+30%	+$83K	0.09%	459
2025 Q4	$225K	Buy	+66,625	New	+$173K	0.09%	498
2025 Q2	–	Sell	-215,843	Closed	-$317K	–	711
2025 Q1	$317K	Buy	215,843 +152,930	+243%	+$364K	0.15%	292
2024 Q4	$279K	Buy	62,913 +46,248	+278%	+$188K	0.12%	420
2024 Q3	$68.7K	Buy	+16,665	New	+$89.6K	0.04%	574
2024 Q2	–	Sell	-10,589	Closed	-$92.2K	–	1254
2024 Q1	$92.2K	Buy	10,589 +8,874	+517%	+$108K	0.08%	474
2023 Q4	$19.6K	Buy	+1,715	New	+$17K	0.02%	1052

Other funds holding IRWD

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

EntryPoint Capital's IRWD Position: Q1 2026 in Review

EntryPoint Capital increased its Ironwood Pharmaceuticals (IRWD) stake by 30% in Q1 2026, buying an estimated $83K and bringing the position to 86,874 shares worth $305K. The position accounts for 0.09% of the portfolio, ranked #459.

EntryPoint Capital first reported a position in IRWD in Q4 2023 and has held it in 7 quarters since. The position peaked at $317K in Q1 2025. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

EntryPoint Capital held 86,874 shares of Ironwood Pharmaceuticals worth $305K as of Q1 2026.
EntryPoint Capital bought 20,249 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $83K.
Ironwood Pharmaceuticals made up 0.09% of EntryPoint Capital's portfolio in Q1 2026, its #459 holding.
EntryPoint Capital first reported a position in Ironwood Pharmaceuticals in Q4 2023 and has held it in 7 quarters since.
EntryPoint Capital's Ironwood Pharmaceuticals position peaked at $317K in Q1 2025.
226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.